AmDen Pharmaceuticals Denmark ApS: Financial statements 2021
CVR: 42045403
Source: annual report 2021, Danish Business Authority
15/01/2021 – 31/12/2021
AmDen Pharmaceuticals Denmark ApS (CVR 42045403) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK 750,332 and a net result of DKK 583,562. Equity in the 2021 report amounted to DKK 623,562. The solvency ratio was 78.4%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 750,332
- Profit/Loss
- DKK 583,562
- Equity
- DKK 623,562
- Total Assets
- DKK 795,138
- Employees
- 1
Official annual report
Find more companies like AmDen Pharmaceuticals Denmark ApS
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2021
As of January 15, 2021, Flemming Dyremose is registered as director of AmDen Pharmaceuticals Denmark ApS.
As of January 15, 2021, Mikael Søndergaard Thomsen is registered as director of AmDen Pharmaceuticals Denmark ApS.
As of January 15, 2021, Thomsen Pharma ApS is registered as an owner of AmDen Pharmaceuticals Denmark ApS with an ownership share of 50%.
As of January 15, 2021, Flandy Holding ApS is registered as an owner of AmDen Pharmaceuticals Denmark ApS with an ownership share of 50%.
AmDen Pharmaceuticals Denmark ApS was founded on January 15, 2021.
About AmDen Pharmaceuticals Denmark ApS
AmDen Pharmaceuticals Denmark ApS is a Danish company of the type Anpartsselskab based in Køge, founded in 2021. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Flemming Dyremose and Mikael Søndergaard Thomsen. The company is owned by Thomsen Pharma ApS and Flandy Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -7,514 and a net result of DKK -4,907 compared with DKK -7,596 the year before. Equity in the 2025 report amounted to DKK 17,994.